Quantcast

Latest Chemotherapy-induced nausea and vomiting Stories

2014-09-22 04:21:55

LUGANO, Switzerland, September 22, 2014 /PRNewswire/ -- Helsinn Group, a company focused on building quality cancer care, today announces that it is supporting an independent educational satellite symposium on Delivering Chemotherapy With Confidence: New Strategies to Minimize Treatment-Induced Nausea and Vomiting at the 38th European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, in 2014. Helsinn has awarded a grant to prIME oncology, a global...

2014-09-09 08:32:33

JUPITER, Fla., Sept. 9, 2014 /PRNewswire/ -- Charleston Laboratories, Inc., an emerging specialty pharmaceutical company focused on the research and development of novel pain products, announced two key clinical updates for the company. The company has submitted an Investigational New Drug Application ("IND") to the U.S Food and Drug Administration ("FDA") Division of Neurology Products (DNP) for the clinical development of CL-H1T as a novel treatment for patients who suffer from...

2014-08-06 20:23:58

Daiichi Sankyo and Charleston Laboratories will collaborate on development and commercialization; Charleston will supply all products and retain an option to co-promote in the United States TOKYO, PARSIPPANY, N.J. and JUPITER, Fla., Aug. 6, 2014 /PRNewswire/ -- Daiichi Sankyo and Charleston Laboratories, Inc., through its wholly owned subsidiary LOCL Pharma, Inc., announced today that the parties have entered into a strategic collaboration for the development and U.S....

2014-07-17 04:20:49

LUGANO, Switzerland and TOKYO, July 17, 2014 /PRNewswire/ -- Under the exclusive agreement, Chugai Pharma Marketing gains rights for the marketing of palonosetron in the UK and NEPA in the UK and in Ireland from Helsinn Group, strengthening the existing alliance between the companies in therapeutic area of supportive cancer care. Helsinn, the Swiss Group focused on building quality cancer care, and Chugai Pharmaceutical Co., Ltd. today announced that exclusive rights to...

2014-07-10 08:27:07

LUGANO, Switzerland, July 10, 2014 /PRNewswire/ -- Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the three Phase 2/3 pivotal trials for the investigational oral fixed-dose combination capsule of netupitant 300 mg + oral palonosetron 0.50 mg (NEPA), which is licensed to Eisai Inc. in the United States, have been published, together with an accompanying editorial, in the July issue of Annals of Oncology....

2014-06-26 08:27:36

WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, June 26, 2014 /PRNewswire/ -- Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed-dose combination of netupitant and palonosetron being evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV), will be presented at the International Symposium on Supportive Care in Cancer. The Multinational Association of Supportive Care in...

2014-05-28 16:26:44

-- Pediatric Patients Aged 1 Month to Less Than 17 Years Now Have A New Option to Help Prevent Acute Chemotherapy-Induced Nausea and Vomiting -- WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, May 28, 2014 /PRNewswire/ -- Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI(®) (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly...

2014-05-08 08:32:34

JUPITER, Fla., May 8, 2014 /PRNewswire/ -- Charleston Laboratories, Inc., an emerging specialty pharmaceutical company focused on the research and development of novel pain products, today announced the company has appointed two new members to its senior executive team. Joseph Hazelton joined the company in the newly created position of Executive Vice President, Chief Commercial Officer, and Michael G. McCully joined the company in the newly created position of Executive Vice...

2014-05-02 08:24:49

JUPITER, Fla., May 2, 2014 /PRNewswire/ -- Charleston Laboratories, Inc., an emerging specialty pharmaceutical company focused on the research and development of novel pain products, today announced the publication of an abstract and presentation of a poster entitled, "Demonstration of the safety and efficacy of CL-108 for moderate-to-severe pain with reduction of opioid-induced nausea and vomiting," at the 2014 Annual Meeting of the American Pain Society being held in Tampa, Florida...

2014-02-04 08:34:50

LONDON, Feb. 4, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2013 Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2013SummaryGlobalData's clinical trial report, "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2013" provides data on the Chemotherapy Induced Nausea and Vomiting clinical trial scenario. This report...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related